The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alekseev I.B.

Russian Medical Academy of Continuous Professional Education

Volkova A.V.

Russian Medical Academy of Continuous Professional Education

Alekseeva L.I.

V.A. Nasonova Research Institute of Rheumatology

Xalacom: possibilities and advantages of the drug in the treatment of patients with glaucoma

Authors:

Alekseev I.B., Volkova A.V., Alekseeva L.I.

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(5): 119‑125

DOI: 10.17116/oftalma2022138051119

Read: 3795 times

Download PDF (RU)
Contact the author
Table of contents

XALACOM: POSSIBILITIES AND ADVANTAGES OF THE DRUG IN THE TREATMENT OF PATIENTS WITH GLAUCOMA
XALACOM: POSSIBILITIES AND ADVANTAGES OF THE DRUG IN THE TREATMENT OF PATIENTS WITH GLAUCOMA

To cite this article:

Alekseev IB, Volkova AV, Alekseeva LI. Xalacom: possibilities and advantages of the drug in the treatment of patients with glaucoma. Russian Annals of Ophthalmology. 2022;138(5):119‑125. (In Russ.)
https://doi.org/10.17116/oftalma2022138051119

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The resu­lts of fistulizing glaucoma surgeries in pseudophackic patients. Russian Annals of Ophthalmology. 2025;(1):45-52
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Electrophysiological methods in the diagnosis and moni­toring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109
The effect of initial conservative hypo­tensive therapy on the outcomes of sele­ctive laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(5):16-22
Modern devi­ces for microinvasive glaucoma surgery. Russian Annals of Ophthalmology. 2025;(5):101-108
Abstract:

The strategy of glaucoma therapy is aimed at preserving visual functions and ensuring an acceptable quality of life for patients. To achieve this strategic goal, clinicians in their practice use drugs that affect the main factor in the progression of the disease — intraocular pressure (IOP), aiming to reduce it to an individual target level. It is not always possible to achieve optimal IOP values with monotherapy. Many patients require a combination of drugs from different pharmacological groups. Xalacom is a fixed drug with good tolerability and t hypotensive effect. This review focuses on the benefits of this drug for the treatment of glaucoma.

Keywords:

glaucoma
hypertensive therapy
fixed combinations
timolol
latanoprost

Authors:

Alekseev I.B.

Russian Medical Academy of Continuous Professional Education

Volkova A.V.

Russian Medical Academy of Continuous Professional Education

Alekseeva L.I.

V.A. Nasonova Research Institute of Rheumatology

Received:

03.08.2022

Accepted:

16.08.2022

Close metadata

References:

  1. World Health Organization. Blindness and vision impairment. Accessed 07.04.22 (In Russ.). https://www.who.int/ru/news-room/fact-sheets/detail/blindness-and-visual-impairment
  2. Malihi M, Sit AJ. Effect of head and body position on intraocular pressure. Ophthalmology. 2012;119(5):987-991.  https://doi.org/10.1016/j.ophtha.2011.11.024
  3. Remington LA. Klinicheskaja anatomija i fiziologija zritel’noj sistemy [Clinical anatomy and physiology of the visual system]: Transl. from English. 3rd ed. M.: Publishing House «Gorodets»; 2020. (In Russ.).
  4. Rukovodstvo po klinicheskoj oftal’mologii [Guide to clinical ophthalmology]. Eds Brovkina A.F., Astakhov Yu.S. M.: LLC «Publishing House «Medicinskoe informacionnoe agentstvo»; 2014. (In Russ.).
  5. Bill A. Uveoscleral drainage of aqueous humor: physiology and pharmacology. Prog Clin Biol Res. 1989;312:417-427. 
  6. Nesterov AP. Glaukoma [Glaucoma]. M.: LLC «Publishing House «Medicinskoe informacionnoe agentstvo»; 2008;360. (In Russ.).
  7. Kanski D. Klinicheskaja oftal’mologija: sistematizirovannyy podhod [Clinical ophthalmology: a systematic approach]: Transl. from English. 2nd ed. Ed. Erichev V.P. M.: Logosphere; 2009;944. (In Russ.).
  8. Alm A, Kaufman PL, Kitazawa Y. Uveoscleral outflow: biology and clinical aspects. London: Mosby—Wolfe; 1998;99. 
  9. Egorov EA. Fixed combination of latanoprost and timolol in the treatment of glaucoma. RMZh. Klinicheskaya oftal’mologiya. 2015;15(2):73-77. (In Russ.).
  10. European Glaucoma Society. Terminology and guidelines for glaucoma, 5th edition. European Glaucoma Society; 2020. Accessed 10.05.22.  https://www.eugs.org.
  11. Nacional’noe rukovodstvo po glaukome: dlyapraktikuyushchihvrachej [National guidelines for glaucoma: for practitioners]. Eds Egorov E.A., Erichev V.P. 4th ed., rev. and additional. M.: GEOTAR-Media; 2019. (In Russ.).
  12. Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostenebunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye. 2020;34(1):72-88.  https://doi.org/10.1038/s41433-019-0671-0
  13. Kuroedov AV, Nagornova ZM, Tibieva ZU, Krinicyna EA, Sergeeva VM. Additive and combined glaucoma therapy: principes and practice. Rossijskij oftal’mologicheskij zhurnal. 2018;11(2):71-81. (In Russ.). https://doi.org/10.21516/2072-0076-2018-11-2-71-81
  14. Andres-Guerrero V, Garcıa-Feijoo J, Konstas AG. Targeting schlemm’s canal in the medical therapy of glaucoma: current and future considerations. Advances in Therapy. 2017;34(5):1049-1069. https://doi.org/10.1007/s12325-017-0513-z
  15. Grieshaber MC, Orguel S, Flammer J.Glaucoma therapy-state of the art. Basel; 2009;178. 
  16. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost,and latanoprost. Current Medical Research and Opinion. 2006;22(5):971-976.  https://doi.org/10.1185/030079906x104777
  17. Kuroyedov AV, Brezhnev AYu, Lovpache JN, Petrov SYu, Tibieva ZU, Nagornova ZM, Krinitsyna EA, Sergeeva VM. The feasibility of adopting «stepwise» initial approaches in treatment of patients with different stages of glaucoma. Nacional’nyj zhurnal glaucoma. 2018;17(4):25-54. (In Russ.). https://doi.org/10.25700/NJG.2018.04.03
  18. Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surgery. 1995;26(3):233-236.  https://doi.org/10.3928/1542-8877-19950501-14
  19. Singh K, Srivastava A. Medical management of glaucoma: Principles and practice. Indian Journal of Ophthalmology. 2011;59(1):88-92.  https://doi.org/10.4103/0301-4738.73691
  20. Kuroedov AV, Abysheva LD, Avdeev RV, Aleksandrov AS, et al. Cost-effectiveness ratio of local hypotensive treatment of patients with moderate and advanced primary open-angle glaucoma (a multicenter study). Rossijskij oftal’mologicheskij zhurnal. 2015;8(3):10-22. (In Russ.).
  21. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953-961.  https://doi.org/10.1016/j.ophtha.2004.12.035
  22. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123(7):898-902.  https://doi.org/10.1001/archopht.123.7.898
  23. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9(9 suppl):2-6. 
  24. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9(6):324-332.  https://doi.org/10.1111/j.1527-5299.2003.03269.x
  25. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Current Opinion in Ophthalmology. 2004;15(2):132-135.  https://doi.org/10.1097/00055735-200404000-00013
  26. Diestelhorst M, Larsson L-I. A 12-Week, Randomized, Double-Masked, Multicenter Study of the Fixed Combination of Latanoprost and Timolol in the Evening versus the Individual Components. Ophthalmology. 2006;113(1):70-76.  https://doi.org/10.1016/j.ophtha.2005.06.027
  27. Kiseleva OA, Bessmertnyi AM. Domestic experience of prescription of fixed combination of latanoprost and timolol maleate in POAG. RMZh. Klinicheskaya oftal’mologiya. 2015;16(3):149-150. (In Russ.).
  28. Radcliffe N. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014;8:2541-2549. https://doi.org/10.2147/OPTH.S76053
  29. Hartleben C, Ayala M, Chaves—Ayala R et al. Morning vs evening use of Xalacom for primary open glaucoma. In: Book of abstracts World Glaucoma Congress. Vienna; 2005;159. 
  30. Martines A, Sanchez M. A four week prospective, randomized, evaluator—masked study of Latanoprost/Timolol compared to Bimatoprost/ Timolol fixed combinations in patients with POAG. In: Book of abstracts 6th Glaucoma symposium. Athens; 2007;127. 
  31. Takmaz T, Aşik S, Kürkçüoğlu P, Gurdal C, Can I. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Eur J Ophthalmol. 2008;18(1):60-65.  https://doi.org/10.1177/112067210801800110
  32. Ozkurt YB, Sengor T, Evciman T, Haboglu M, Bas G, Aydin S. Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg. Clin Ophthalmol. 2009;3:337-339.  https://doi.org/10.2147/opth.s5128.
  33. Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011;20(4):215-222.  https://doi.org/10.1097/IJG.0b013e3181e08121
  34. Astakhov YuS, Goziev SJ, Shikhaliev DJ. The influence of unfixed and fixed combination of Timolol 0.5 % and Latanoprost 0.005 % on local and systemic hemodynamics in treatment of patients with POAG. Oftal’mologicheskie vedomosti. 2009;2(1):12-17. (In Russ.).
  35. Miglior S, Grunden J, Kwok K et al. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye. 2010;24(7):1234-1242. https://doi.org/10.1038/eye.2009.307
  36. He M, Wang W, Huang W. Efficacy and tolerability of the fixed combinations latanoprost/ timolol versus dorzolamide/ timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLOS one. 2013;8(12):e83606. https://doi.org/10.1371/journal.pone.0083606
  37. Fuma S, Shimazawa M, Imamura T, Kanno Y, Takano N, Tsuruma K, Hara H. Neuroprotective Effect of Ocular Hypotensive Drugs: Latanoprost/ Timolol in Combination Are More Effective than Each as Monotherapy in RGC-5. Biol Pharm Bull. 2016;39(2):192-198.  https://doi.org/0.1248/bpb.b15-00584
  38. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Ksalakom P N013924/01. (In Russ.).
  39. Inoue K, Fujimoto T, Higa R, et al.Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eye drops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012;6:771-775. 
  40. Hamacher T, Schinzel M, Schölzel-Klatt A, et al., Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies, British Journal of Ophthalmology. 2004;88:1295-1298.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.